Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amira Pharmaceuticals has commenced a Phase 1 clinical study of AM152, a novel LPA1 antagonist, in normal, healthy subjects.
Subscribe to our email newsletter
Amira Pharma Clinical Development vice president Isabelle DeArmond said that they are excited to begin their journey exploring the therapeutic value of AM152, a potentially novel anti-fibrotic agent.
"Our first step is to understand the safety, pharmacodynamic (PD) and pharmacokinetic (PK) profile of this compound in normal healthy subjects," DeArmond said.
"We expect to have these studies completed by the middle of next year, and assuming positive results, we could then begin to study the therapeutic utility of AM152 in patients."
Amira Pharma CEO Bob Baltera said that currently, there are no FDA-approved therapies for fibrotic disease, and we look forward to better understanding the potential therapeutic benefit of an LPA1 antagonist in this area of medicine.